Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 485 participants.

Also called NCT01353469

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 485 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01353469
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01353469. Randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Acronym
Insuman-C25-CN
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin human/Insuman Comb 25 (HR1799)
Intervention (Drug)
Insulin human/Novolin® 30R
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01353469
Content hash
47904ab85d5bc3334a338dbbeb5c44e1600da2beeb5ec7dee0d50a934a0faa4b